Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.

摘要: Abstract Background HE4, a novel tumor marker for detecting ovarian cancer, has been recently applied to clinical practice. However, the comprehensive evaluation of HE4 combined with other markers is still missing. We evaluated an optimal mode employment differential diagnosis benign and malignant pelvic masses. Methods Serum CA125, CA153, CA199, CA211 CA724 were measured from 232 patients messes (100 masses, 132 diseases), risk malignancy algorithm (ROMA) was also calculated. Receiver operating characteristic curves (ROC), area under curve (AUC), sensitivity specificity estimated. Results The combination CA125 (AUC 0.963, 96.6%, 65.7%) provided best power in diagnosing cancer. ROMA performed better masses 0.917, 82.0%, 78.8%) uterine cancer 0.838, 60.0%) compared applying individually. Conclusion cut-off values (CA125: 93.2 U/ml, HE4: 87.6 pmol/l, ROMA: 18.1% pre- 31.5% postmenopausal women), simultaneous use complemented by showed performance than traditional detection modes observed that added more accuracy differentiating auxiliary